Grail published PATHFINDER 2 results showing improved positive predictive value (PPV) and a sensitivity of 40.4% for its Galleri multi‑cancer screening test in nearly 36,000 adults over age 50. The company reported that more than half of detected cancers were early‑stage and that roughly 62% of positive tests corresponded to confirmed cancer diagnoses in follow‑up. The data, disclosed ahead of an FDA filing, bolster Grail’s argument that multi‑cancer blood tests can detect cancers not covered by current screening programs. Analysts noted that while sensitivity remains moderate, the higher PPV strengthens the regulatory case—though questions persist about downstream follow‑up pathways and population‑level benefits. Grail plans to use the PATHFINDER 2 dataset to support broader rollout plans and regulatory submissions.